With the GKV Contribution Rate Stabilization Act, around 65,000 statutory health insurance patients are losing reimbursement for dried cannabis flowers. What this means for people who depend on precise control of their therapy is illustrated by the case of Kevin Anahid. A conversation about titrability, language, and participation.
We have detailed the specifics of the new regulation in our report on how the Bundestag removes cannabis flowers from insurance reimbursement. Kevin Anahid is a sociologist who lives with tetraspastic cerebral palsy in Hamburg and has been treating spasticity and pain for eight years with medically supervised inhalative cannabis flowers. He contacted us with a press statement. In the interview, he explains why the forced switch is not a neutral therapy change for him. The following account reflects his personal perspective and his medically documented experience; it is not general medical advice.
Why the specific form of administration is so decisive for him, why this is not just about pain and spasticity but about his speech and thus about participation, and what legal questions the case raises—he describes this in the following conversation. The sources and evidence he cites can be found at the end of this article.
Interview
Kevin Anahid, Sociologist and Cannabis Patient
On eight years of therapy with inhalative flowers, the consequences of the reimbursement cut, and the question of what participation really means.
Question 1
Could you briefly introduce yourself? What does your cannabis therapy look like, and how did you come to it eight years ago?
Kevin Anahid: I’m Kevin Anahid, academically trained sociologist with a legal background, from Hamburg. I live with tetraspastic cerebral palsy and use a wheelchair. For about eight years, I have been continuously treated under medical supervision with cannabis flowers; my health insurance approval has been in place since May 2020. The starting point was controlling spasticity and pain after the standard therapies provided for in the law under § 31 para. 6 SGB V (old version) had already been exhausted and documented as ineffective. I observe this case consciously on two levels simultaneously: as someone affected who experiences the effect in his own body, and as a social scientist who places this experience in a structural context. This dual perspective is important to me because it prevents individual suffering and societal analysis from being played against each other.
Question 2
For you, the inhalative flower form is specifically decisive. Can you explain what real-time titration means and why an oral preparation cannot achieve this for you?
Kevin Anahid: The difference is pharmacological, not a comfort factor: inhalation allows real-time titration—I can counter an acute pain spike or spastic episode within minutes. Oral extracts like Sativex take 60 to 120 minutes to work. This delay means: when the effect sets in, the acute episode has usually either already subsided or escalated uncontrollably; the controllability is structurally absent. For me, this is more than a pharmacological detail: it determines whether I can participate as an agent capable of action in an interaction at any given moment or not.
Question 3
You say the switch concretely affects your speech intelligibility. How is this connected to your underlying condition and muscle tone?
Kevin Anahid: My underlying condition also affects the orofacial and respiratory muscles responsible for articulation. When muscle tone exceeds a certain level, my speech becomes unintelligible to those around me—to care workers, doctors, family members. Sociologically speaking, this determines whether a successful reciprocal relationship, in the sense of resonant, mutually responsive understanding, can come about at all, or whether it breaks off at the crucial moment. Because the inhalative flower works in real time, I can intercept rising muscle tone during a conversation and maintain this reciprocal relationship. With a delayed-acting preparation, this time window is exactly what’s missing, and precisely in the moment when understanding is most urgently needed.
Question 4
What changes for you in very practical terms with this law, especially given the six-month reimbursement exclusion for compounded medications during the transition?
Kevin Anahid: Reimbursement for flowers is eliminated entirely; I’m directed to a finished pharmaceutical product. Adding to this problem is the fact that cannabinoid-containing compounded medications are also excluded from reimbursement for the first six months of a therapy switch, so the alternative provided for in the law is factually unavailable during the transition. Flowers remain available via private prescription, but are no longer reimbursable. From a sociological perspective, this is a textbook example of how a formally neutral regulation factually sorts by economic capital, not by medical need.
Question 5
The finished pharmaceutical intended as a replacement has, according to the product information, a multi-week titration phase and typical side effects. How do you experience or anticipate the switch?
Kevin Anahid: According to Sativex product information, a multi-week titration phase is necessary to find the individually optimal dose, and side effects occur most severely during this phase: very frequently dizziness and fatigue (in over 10 percent of users), frequently dry mouth. These are not merely bodily side effects: dizziness and especially persistent fatigue directly impact my cognitive performance—I can concentrate less well, follow thoughts more slowly, and conduct conversations less attentively, as medically documented and not merely subjectively felt. In my own treatment course, this already appears: side effects I could control under the flower through years of experience, such as persistent dry eyes, recur with Sativex and are barely controllable for me. In combination with the lack of real-time controllability, this is not a neutral alternative but an additional burden affecting precisely those cognitive and communicative abilities through which I have worked to achieve societal participation over years.
Question 6
You invoke Article 3 of the Basic Law, the UN Convention on the Rights of Persons with Disabilities, and reliance protection. Where do you see the structural disadvantage, especially for exhausted patients under Section 31 Paragraph 6 SGB V?
Kevin Anahid: I see a structural, not accidental collision with the participation mandate: Article 3 paragraph 3 sentence 2 of the Basic Law prohibits discrimination based on disability; Articles 19 and 26 of the UN Convention on the Rights of Persons with Disabilities obligate full societal participation and rehabilitation according to individual need; § 2 SGB IX defines participation as a legal entitlement. Particularly affected are exhausted patients who originally had to earn access to flowers precisely by proving they had no alternatives under § 31 para. 6 SGB V (old version). The new law withdraws care from exactly this group without an opening clause for already individually approved existing cases. Analytically, this is a shift from individual needs assessment to blanket categorization, a form of structural disadvantage that does not manifest as open discrimination but rather in administrative logic that prioritizes cost efficiency over the participation entitlement anchored in law. Additionally, I see reliance protection under Article 20 paragraph 3 of the Basic Law in conjunction with Article 2 paragraph 2 of the Basic Law as affected, because a continuously granted benefit designed for continuity is withdrawn without adequate transition provisions.
Question 7
Flowers remain available via private prescription, just no longer reimbursed. What does this de facto distinction based on ability to pay mean for those affected?
Kevin Anahid: Those who can afford the therapy privately lose nothing. Those who depend on public health insurance coverage lose access entirely. The law thus factually differentiates by income, not by medical necessity, for an exhausted patient group that by definition cannot work toward any other option. When you look at distribution questions as a social scientist, you recognize a familiar pattern here: access to a good that should actually be need-driven becomes coupled to economic capital via the detour of reimbursability.
Question 8
As a sociologist, you think about participation beyond your individual case. What would need to change, and what specifically do you wish from the legislature—perhaps an opening clause for documented existing cases?
Kevin Anahid: I share the position of the Federal Association of German Cannabis Patients, which demanded during the legislative process that changes to existing therapies only occur after individual medical review, not through blanket exclusion of an entire form of administration. Specifically, I wish for an opening clause for documented, already individually approved existing cases like mine. My demand is not only that of someone affected seeking relief, but of an expert pointing to internally contradictory legislative logic: a regulation intended to reduce costs by cutting back precisely those abilities that enable people with disabilities to contribute independently, critically, and economically produces higher societal and institutional follow-up costs in the long term. Inclusion cannot end where people with disabilities, despite their disabilities, wish to remain self-determined, capable, and intelligible.
Frequently Asked Questions on the Elimination of Flower Reimbursement
Why are cannabis flowers no longer reimbursed by health insurance?
With the GKV Contribution Rate Stabilization Act, reimbursement for dried cannabis flowers is eliminated for around 65,000 statutory health insurance patients. For compounded medications, an additional six-month reimbursement exclusion applies during the transition. How this came about is shown in the report on the first Bundestag reading on the reimbursement elimination.
Are medical cannabis flowers still available?
Yes. Flowers remain available via private prescription but are no longer covered by statutory health insurance. This means care access is factually dependent on ability to pay. Exchange and orientation for those affected is offered through, among others, a forum for cannabis patients.
What does the switch from flowers to oral preparations mean?
Inhalative flowers allow real-time titration, meaning precise dose control at the moment of use. Oral finished pharmaceuticals only achieve stable adjustment over a multi-week titration phase according to product information. For some patients, this concretely affects muscle tone, speech intelligibility, and participation. On the political background: the Finance Commission’s call for an end to statutory health insurance reimbursement.
What legal bases do affected patients cite?
Affected patients refer to the principle of equality under Article 3 of the Basic Law, the UN Convention on the Rights of Persons with Disabilities, and reliance protection for exhausted patients under Section 31 Paragraph 6 SGB V. How other countries regulate access to cannabis for sick people is shown, for example, by looking at France.
Sources and Evidence
- Medical statement on diagnosis, cognitive impairment, and tone-related speech impairment (held by the author), 12.05.2026
- Legal bases: Art. 3 para. 3 s. 2 GG; Art. 19, 26 UN Convention on the Rights of Persons with Disabilities; § 2 SGB IX
- Legislative process: GKV Contribution Rate Stabilization Act, passed by Bundestag 10.07.2026, BT-Drs. 21/6130; Bundesrat waived mediation committee on the same day
- Transition provision for compounded medications: § 31 para. 6 SGB V (new version) (six-month waiting period)
- Position of patient organization: Statement of the Federal Association of German Cannabis Patients (BDCan) to the public hearing of the Health Committee, 22.06.2026
- Approval of insurance benefit: Insurance approval letter, May 2020
- Side effect profile: Product information Sativex (nabiximols), multi-week titration phase; very frequent side effects (more than 1 in 10 users): dizziness, fatigue; frequent side effect: dry mouth
Sollten Cannabisblüten weiter von der Krankenkasse erstattet werden?
This interview reflects the personal perspective and medically documented experience of Kevin Anahid. This is an account of an individual case and does not constitute general medical advice. This article is not a substitute for medical consultation. Medications mentioned are referenced exclusively within the framework of this account of experience and the respective product information.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
